What changed
$SYK — WATCHLIST 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $6.0B | EPS $2.60 vs $2.98 🔴 | Margin 25.7%
💡 Consensus expected $2.98 in Q1 and may have extrapolated the miss to lower full-year estimates, while management maintained FY EPS of $14.90-$15.10, implying sharply accelerating earnings in remaining quarters.
📉 Reward/risk: 1.92:1
🏢 Business Quality: 9 — dominant moat in orthopedics and surgical equipment with high recurring revenue and strong margins./10
📊 Valuation: fair — forward P/E ~20.9x on FY EPS midpoint $15.00, within historical 18-25x range and in line with premium peers; DCF supports $290-$340 range...
🔮 Catalyst: Q2 2026 earnings report
💰 Entry: $313.68, stop $300, target $340
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/SYK0625